ClinicalTrials.gg
RecruitingNCT06639256Updated Oct 13, 2026

Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of Test Product HY07121 in Safety, Tolerability and Efficacy, sponsored by Sichuan Huiyu Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Sichuan Huiyu Pharmaceutical Co., Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
258
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 in participants with advanced solid tumors.

Read the detailed description

The study starts with a dose escalation part (Part 1) followed by a dose expansion part (Part 2). The main purpose of this study is to evaluate the safety and tolerability of the drug HY07121 and determine the maximum tolerated dose (MTD) (if any) and/or the recommended dose(s) (RD) and preliminary anti-tumor activity. Additional purposes of the study are to evaluate the pharmacokinetics (PK) properties, immunogenicity, correlation of the biomarkers and PK profile with anti-tumor activity.

02

Conditions studied

  • Safety
  • Tolerability
  • Efficacy
03

In context

Lead sponsor

Sichuan Huiyu Pharmaceutical Co., Ltd is the lead sponsor of 16 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written ;
  • ≥18 years old and ≤80 years old, gender: male or female;
  • or cytologically confirmed unresectable advanced/ solid tumor that has or progressed on or after standard systemic treatments, or refused the standard treatment, or for which no standard treatment is available;
  • Presence of at least one according to (RECIST) Version 1.1;
  • (ECOG) performance status score is 0 or 1;
  • ≥3 months;
  • Participant must have adequate main organ function;
  • Fertile female patients must have a negative serological pregnancy test within 7 days before the first dosing and be willing to use effective /contraception to prevent pregnancy during the study period up to 6 months after the last dosing of the study. Male patients must agree to have no sperm donation plans and to use effective contraceptive methods during the study period until 6 months after the last dose of the study. women must have amenorrhea for at least 12 months before they are considered infertile.

Exclusion criteria

Exclusion Criteria:

  • Within the defined for prior anti-cancer treatments;
  • Participant is currently participating or has participated in a study of an agent or using an investigational device within 4 weeks of first dose of HY07121.
  • Any other within 2 years prior to the first dose of the study treatment except for localized cancers that are considered to have been cured and in the opinion of the Investigator present a low risk for recurrence.
  • Participant has not recovered (i.e., to Grade 1 or to baseline) from previous anticancer therapy-induced Adverse Events (AEs).
  • Participants with a history of recently (within previous 2 years of the first dose of the study treatment) active diverticulitis or symptomatic peptic ulcer disease;
  • Major surgery within 4 weeks of receiving the first dose of study treatment;
  • Participant has Symptomatic Central Nervous System (CNS) , or requiring CNS-directed local therapy (such as radiotherapy or surgery) or therapy within 4 weeks of first dose of study treatment;
  • Participants with untreated or under treatment for tuberculosis, including but not limited to tuberculosis; Patients who have received standardized anti-tuberculosis treatment and have been confirmed cured by the researchers can be included;
  • Participants with cardiovascular diseases, in the past 6 months prior to the first dose of the study treatment; symptomatic coronary heart disease requiring drug treatment; arrhythmia requiring drug treatment; or uncontrolled hypertension;
  • Known (HIV) infection or known Acquired Immunodeficiency Syndrome (AIDS);
  • Active or chronic or infection; treponema pallidum antibody positive, and confirmed positive test;
  • Active known or suspected disease.
  • History of non-infectious pneumonitis that has required a course of oral or intravenous steroids to assist with recovery, or interstitial lung disease or severe obstructive pulmonary disease;
  • History of severe allergy;
  • History of allogeneic organ transplantation or ;
  • Have received live/attenuated vaccines and mRNA vaccines within 4 weeks prior to screening or plan to receive live/attenuated vaccines and mRNA vaccines during the study period;
  • Any active infection requires systemic treatment via intravenous infusion within 4 weeks prior to the first dose of study treatment;
  • Known psychiatric disorder or drug abuse that would interfere the trial requirements;
  • Participant with uncontrolled pleural effusion, pericardial effusion or peritoneal effusion or need drainage;
  • In addition to the tumors present at the time of entry into the study, other active malignancies were present within 3 years prior to the first dose (not excluding locally cured tumors, such as skin basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the breast, etc.);
  • Participants considered unsuitable for participation in this study by the investigators.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
258 participants (estimated)

Study arms

  • Experimental
    Test product HY07121 for Dose Escalation

    PART ONE- Dose escalation: HY07121 should be administered intravenously at recommended dose. The purpose of the Dose Escalation Phase (Part one) is to characterize the safety and tolerability of the test product HY07121 and determine the maximum tolerated dose (MTD) (if any) and/or the recommended dose(s) (RD) based on the frequency of the occurrence of Dose-Limiting Toxicity (DLT) in each cohort during the DLT evaluation period.

    Drug: Test Product HY07121

  • Experimental
    Test product HY07121 for Dose Expansion

    PART TWO- Dose expansion: HY07121 should be administered intravenously at recommended dose. Patients will be administered a recommended dose of HY07121 established from the Dose Escalation Phase of the study.

    Drug: Test Product HY07121

Interventions

  • DrugTest Product HY07121

    HY07121 should be administered intravenously at recommended dose.

    Also known as: HY0007-101

06

What researchers measure

Primary outcomes

  1. Dose Escalation (Part One): Incidence and Nature of Dose-Limiting Toxicity (DLT)

    Dose-Limiting Toxicity (DLT) will be defined using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 or American Society for Transplantation and Cellular Therapy (ASTCT) criteria for Cytokine Release Syndrome (CRS).

    Time frame: 21 days during the first 3-week cycle

  2. Dose Escalation (Part One): Percentage of participants experiencing treatment-emergent adverse events (TEAEs)

    Incidence and severity of adverse events (AEs), serious adverse events (SAEs), and lab abnormalities, according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading

    Time frame: Up to 2 years

  3. Dose Escalation (Part One): Percentage of participants experiencing Adverse Event (AE) related dose interruptions, dose delays, and dose intensity

    Occurrence of Adverse Event (AE) related dose interruptions, dose delays and dose intensity (duration of HY07121 exposure)

    Time frame: Up to 2 years

  4. Dose Expansion (Part Two): Objective Response Rate (ORR)

    Proportion of participants who have a confirmed Complete Response (CR) or a Partial Response (PR)

    Time frame: Up to 2 years

Secondary outcomes

  1. Dose Expansion (Part Two): Percentage of participants experiencing treatment-emergent adverse events (TEAEs)

    Incidence and severity of adverse events (AEs), serious adverse events (SAEs), and lab abnormalities, according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading

    Time frame: Up to 2 years

  2. Dose Expansion (Part Two): Percentage of participants experiencing adverse event (AE) related dose interruptions, dose delays, and dose intensity

    Occurrence of adverse event (AE) related dose interruptions, dose delays and dose intensity (duration of HY07121 exposure).

    Time frame: Up to 2 years

  3. Dose Escalation and Expansion: Assessment of HY07121 Cmax

    Maximum concentration observed (Cmax) observed from the pharmacokinetic profile

    Time frame: Up to 2 years

  4. Dose Escalation and Expansion: Assessment of HY07121 AUC

    Area under the concentration versus time curve calculated using the trapezoidal method

    Time frame: Up to 2 years

  5. Dose Escalation and Expansion: Assessment of HY07121 T1/2

    The time it takes for half the drug concentration to be eliminated calculated using slope of the terminal line

    Time frame: Up to 2 years

  6. Dose Escalation and Expansion: Assessment of HY07121 anti-drug-antibody (ADA)

    Incidence, duration, titer of serum anti-HY07121 antibody (ADA)

    Time frame: Up to 2 years

  7. Dose Escalation (Part One): Objective Response Rate (ORR)

    Proportion of participants who have a confirmed complete response (CR) or a Partial Response (PR) determined by Investigator per the Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1

    Time frame: Up to 2 years

  8. Dose Escalation and Expansion: Duration Of Response (DOR) assessed by investigator per Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1

    Duration Of Response (DOR) is defined as the time from the measurement criteria are first met for complete response (CR) /Partial Response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease.

    Time frame: Up to 2 years

  9. Dose Escalation and Expansion: Disease Control Rate (DCR) assessed by investigator per RECIST Version 1.1

    Disease Control Rate is defined as the percentage of participants who have achieved CR or PR or have demonstrated stable disease

    Time frame: Up to 2 years

  10. Dose Escalation and Expansion: Progression-Free Survival (PFS) assessed by investigator per RECIST Version 1.1

    Progression-Free Survival (PFS) is defined as the time from the date of first administration of HY07121 to the date of the first documented disease progression determined by Investigator as per RECIST 1.1 or death from any cause, whichever occurs first

    Time frame: Up to 2 years

  11. Dose Escalation and Expansion: Time-To-Progression (TTP) assessed by investigator per RECIST Version 1.1

    Time-To-Progression (TTP) is defined as the time from the date of first administration of HY07121 to the date of the first documented disease progression

    Time frame: Up to 2 years

  12. Dose Escalation and Expansion: Overall Survival (OS)

    Overall Survival (OS) is defined as the time from the date of first administration of HY07121 to death due to any cause

    Time frame: Up to 2 years

  13. Dose Escalation and Expansion: The correlation between tumor biomarkers and efficacy

    Objective Response Rate (ORR) is defined as proportion of participants who have a confirmed Complete Response (CR) or a Partial Response (PR) determined by Investigator per RECIST version 1.1. Tumor biomarkers will be tested using Immunohistochemistry (IHC) and scored using Tumor Proportion Score (TPS) and/or Combined Positive Score (CPS) algorithm.

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2024 (actual). Primary completion is estimated for May 2027, 31 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion May 2026 → May 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2024
First posted
Oct 15, 2024
StartActual
Oct 24, 2024
Primary completionEst.
May 26, 2027was May 2026
CompletionEst.
Oct 26, 2027was Oct 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 2026→May 26, 2027
Oct 13, 2026
Study completion
Oct 2026→Oct 26, 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion May 2026→May 26, 2027
    Study completion Oct 2026→Oct 26, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06639256
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Oct 24, 2024
Primary completion
May 26, 2027 (estimated)
Completion
Oct 26, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Jinmin Yu, Doctor
Contact
sdyujinming@126.com
+86-521-67626971
Huiyura666! Yu, Doctor
principal investigator · Shandong Cancer Hospital and Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion